Episode Details

Delaware’s state employees are facing skyrocketing prescription drug costs, especially for popular weight-loss meds, as a new report reveals the state can’t force pharmacy middlemen—PBMs—to lower prices without risking costly rebates. Lawmakers hoped the board would demand more transparency and better deals, but the report warns that bypassing PBMs could backfire financially. Senator Ray Seigfried blasts the findings as too timid, calling for federal and state action to expose hidden costs. The state is also exploring multi-state negotiations with drugmakers, though that too may cost them current discounts. Meanwhile, the Department of Justice is already suing PBMs and manufacturers over alleged price-gouging in diabetes treatments—highlighting how tangled and unfair the prescription drug system has become.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/5f647a538e0bbaf7